BOSTON SCIENTIFIC CORP 8-K

What Happened

• Boston Scientific Corporation announced on January 15, 2026 that it has executed a definitive agreement to acquire Penumbra, Inc. The acquisition agreement was entered into by Boston Scientific, its wholly owned subsidiary Pinehurst Merger Sub, Inc., and Penumbra. The company issued a joint press release and posted an investor presentation about the transaction, and will hold a conference call at 8:00 a.m. ET on January 15, 2026 to discuss the deal.

Key Details

• Agreement executed: Boston Scientific, Pinehurst Merger Sub, Inc. (wholly owned), and Penumbra, Inc. (Delaware) — definitive agreement executed Jan 15, 2026.
• Investor communication: joint press release and investor presentation made public and attached to the 8-K as Exhibits 99.1 and 99.2.
• Conference call: scheduled for 8:00 a.m. ET on January 15, 2026; materials available on Boston Scientific’s website.
• Filing: disclosed under Item 7.01 (Regulation FD Disclosure); exhibits listed under Item 9.01.

Why It Matters

• This 8-K signals a major corporate transaction — an announced acquisition — and provides the primary public materials (press release and investor presentation) investors should review. The conference call and exhibits are the company’s first public disclosures with transaction details; investors should listen to the call and read the attached presentation for specifics such as deal terms, strategic rationale, timing, and any required approvals. Information on third‑party or company websites linked from those materials is not incorporated into the 8-K.